Cellectis Logo.png
Monthly information on share capital and company voting rights
02 oct. 2024 16h30 HE | Cellectis Inc.
PARIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Logo.png
Monthly information on share capital and company voting rights
04 sept. 2024 16h30 HE | Cellectis Inc.
PARIS, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Logo.png
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
26 août 2024 16h30 HE | Cellectis Inc.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Logo.png
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
07 août 2024 02h00 HE | Cellectis Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Logo.png
Cellectis Provides Financial Results for the Second Quarter 2024
06 août 2024 16h30 HE | Cellectis Inc.
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273...
Cellectis Logo.png
Monthly information on share capital and company voting rights
05 août 2024 16h30 HE | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Cellectis Logo.png
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
01 août 2024 16h30 HE | Cellectis Inc.
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
10 juil. 2024 08h05 HE | Tevogen Bio Inc
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
Cellectis Logo.png
Monthly information on share capital and company voting rights
05 juil. 2024 16h30 HE | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...
Cellectis Logo.png
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
28 juin 2024 16h30 HE | Cellectis Inc.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...